Who were sapropterin's key developers?

Who originally developed sapropterin (before it became commercially marketed)?

Sapropterin is the synthetic form of tetrahydrobiopterin (BH4), a molecule involved in nitric oxide production and amino-acid metabolism. The work that led to sapropterin as a therapy built on decades of biochemical research into BH4 biology, including how BH4 deficiency causes hyperphenylalaninemia and how supplying BH4 can reduce phenylalanine levels. The clinical development of BH4/sapropterin for hyperphenylalaninemia is closely associated with researchers and institutions that studied BH4-dependent pathways in inherited metabolic disorders and then translated that biology into treatment for conditions such as phenylketonuria and BH4-responsive hyperphenylalaninemia [1].

Which specific teams or labs are credited in the literature as key developers?

The most commonly cited “developer” identities for sapropterin in accessible summaries are the researchers who:
1) established BH4 deficiency as a treatable cause of phenylalanine disorders, and
2) carried out early clinical studies testing synthetic BH4/sapropterin in affected patients.

However, the provided information does not list named individuals (e.g., specific principal investigators or inventor names), so I can’t reliably identify “key developers” by person without risking inaccuracies.

Can you share a product or context (so I can name people accurately)?

If you tell me which context you mean, I can answer precisely:
- the first clinical trials for sapropterin in BH4-responsive hyperphenylalaninemia (who ran them),
- the inventors credited on sapropterin-related patents (which names appear as inventors),
- or the company-backed development leading to the brand name (including leadership/scientific authors).

If you share one of the following—brand name (e.g., Kuvan), a link, or a trial/patent number—I can pinpoint the key developers tied to that specific origin.

Source

1. https://en.wikipedia.org/wiki/Sapropterin